Sharon Hashmueli
Regulatory Affairs
Nanothinx
Israel
Biography
Over 15 years of experience in CMC and regulatory product development of recombinant proteins and antibodies. Sharon was the former VP of Regulatory and Clinical Affairs at cCAM Biotherapeutics. Prior to that, she was instrumental at Protalix Biotherapeutics (NASDAQ: PLX) where she played a significant role in the development of Elelyso, an FDA approved treatment for Gaucher disease.
Research Interest
Regulatory Affairs
